These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25101989)

  • 1. Crohn's disease successfully treated with infliximab in a patient receiving hemodialysis: case report and review of the literature.
    Chiba M; Tsuda S; Tsuji T; Nakane K; Komatsu M; Miura Y; Ishida T; Shibahara T; Nishimoto T
    Medicine (Baltimore); 2014 Aug; 93(7):e54. PubMed ID: 25101989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of Crohn's disease having normal delivery after infliximab treatment during early pregnancy].
    Jang YW; Park YS; Kim SH; Jo YJ; Jo YK; Ahn SB; Seo YS; Hong YO
    Korean J Gastroenterol; 2013 Jan; 61(1):37-41. PubMed ID: 23354348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
    Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic lupus erythematosus complicated by Crohn's disease: a case report and literature review.
    Yamashita H; Ueda Y; Kawaguchi H; Suzuki A; Takahashi Y; Kaneko H; Kano T; Mimori A
    BMC Gastroenterol; 2012 Dec; 12():174. PubMed ID: 23216789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial.
    Yoshida K; Fukunaga K; Ikeuchi H; Kamikozuru K; Hida N; Ohda Y; Yokoyama Y; Iimuro M; Takeda N; Kato K; Kikuyama R; Nagase K; Hori K; Nakamura S; Miwa H; Matsumoto T
    Inflamm Bowel Dis; 2012 Sep; 18(9):1617-23. PubMed ID: 22081474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of infliximab induction therapy on secondary systemic amyloidosis associated with Crohn's disease: case report and review of the literature.
    Pukitis A; Zake T; Groma V; Ostrovskis E; Skuja S; Pokrotnieks J
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):333-6. PubMed ID: 24078992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab treatment of pediatric refractory Crohn's disease: a case report.
    Akman SA; Arikan C; Sözen G; Oztürk C; Yağci RV
    Turk J Gastroenterol; 2006 Jun; 17(2):133-6. PubMed ID: 16830299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful use of maintenance infliximab for nephropathy in a patient with secondary amyloidosis complicating Crohn's disease.
    Tada Y; Ishihara S; Ito T; Matsui K; Sonoyama H; Oka A; Kusunoki R; Fukuba N; Mishima Y; Oshima N; Moriyama I; Yuki T; Kawashima K; Sato S; Adachi K; Ikeuchi H; Kinoshita Y
    Intern Med; 2013; 52(17):1899-902. PubMed ID: 23994979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
    Gordon M; Taylor K; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab therapy for Crohn's-like disease in common variable immunodeficiency complicated by massive intestinal hemorrhage: a case report.
    Akazawa Y; Takeshima F; Yajima H; Imanishi D; Kanda T; Matsushima K; Minami H; Yamaguchi N; Ohnita K; Isomoto H; Hayashi T; Nakashima M; Nakao K
    BMC Res Notes; 2014 Jun; 7():382. PubMed ID: 24952714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature.
    Verma S; Kroeker KI; Fedorak RN
    BMC Gastroenterol; 2013 Apr; 13():59. PubMed ID: 23556424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M; Duricova D; Malickova K; Machkova N; Bouzkova E; Hrdlicka L; Komarek A; Lukas M
    J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
    Chauvin A; Le Thuaut A; Belhassan M; Le Baleur Y; Mesli F; Bastuji-Garin S; Delchier JC; Amiot A
    Dig Liver Dis; 2014 Aug; 46(8):695-700. PubMed ID: 24893686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.
    Szabó D; Kökönyei G; Arató A; Dezsőfi A; Molnár K; Müller KE; Lakatos PL; Papp M; Lovász BD; Golovics PA; Cseh A; Veres G
    J Crohns Colitis; 2014 Aug; 8(8):747-55. PubMed ID: 24434181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.